served between eukaryotes, consists of NH 2 CH 2 CH 2 -PO 4 H-6Man␣1-2Man␣1-6Man␣1-4GlcN␣1-6-D-myoinositol-1-HPO 4 -lipid, where the lipid can be diacylglycerol, lyso-acylglycerol, alkylacylglycerol, or ceramide, and is often further decorated with additional ethanolamine phosphate and/or carbohydrate groups and/or fatty acid attached to the inositol residue (inositol acylation) in a species-and tissue-specific manner. Biosynthesis of GPI in T. brucei ( Figure 1, panel a) , which occurs in the endoplasmic reticulum, is initiated by the transfer of GlcNAc from UDP-GlcNAc to phosphatidylinositol (PI) to generate N-acetyl-glucosaminylphosphatidylinositol (1, GlcNAc-PI), which is de-N-acetylated to produce glucosaminylphosphatidylinositol (2, GlcN-PI) (17) . De-N-acetylation is a prerequisite for the subsequent mannosylation of GlcN-PI (18) , which requires the sequential action of three distinct mannosyltransferases (MTI, MTII, and MTIII) to form trimannosyl-glucosaminylphosphatidylinositol (Man 3 GlcN-PI). MTIII, a Dol-P-Man: Man 2 GlcN-PI ␣(1-2) mannosyltransferase, has been shown genetically to be essential in bloodstream form T. brucei (4) . From GlcN-PI onward there are significant differences in the GPI biosynthetic pathways of T. brucei and mammalian cells. In T. brucei, inositol acylation occurs only after addition of the first mannose and is only essential for the addition of ethanolamine phos- www.acschemicalbiology.org phate to the third mannose, whereas in mammalian systems GlcN-PI undergoes inositol acylation before mannosylation occurs (19, 20) .
No high resolution structural data exists for any of the enzymes of the GPI biosynthetic pathway, and given that the enzymes contain between 1 and 13 predicted transmembrane domains and/or are components of multiprotein complexes, such structural data may prove difficult to obtain. The substrate specificity of the early enzymes of the T. brucei and HeLa GPI biosynthetic pathways have been examined in vitro using synthetic substrate analogues (7, 18, 21−27) . The T. brucei de-Nacetylase and MTI enzymes have less stringent substrate recognition compared with those of the mammalian pathway, enabling substrate-based species-specific inhibitors to be designed (23, 25, 26) . However, little is known about the substrate specificity of enzymes late in the GPI biosynthetic pathway. Here, we use a chemical biological approach, analogous to site-directed mutagenesis of a protein, to characterize substrate recognition by essential enzymes late in the trypanosomal GPI biosynthetic pathway. 7  8  9  10  11  12  13  14  15  16  17  18  19  20   Name   Man 2 GlcN-lPC 18  2-deoxyMan 2 GlcN-lPC 18  3-deoxyMan 2 GlcN-lPC 18  4-deoxyMan 2 GlcN-lPC 18  2′-deoxyMan 2 GlcN-lPC 18  3′-deoxyMan 2 GlcN-lPC 18  4′-deoxyMan 2 GlcN-lPC 18  6′-deoxyMan 2 GlcN-lPC 18  2′-fluoroMan 2 GlcN-lPC 18  3′-fluoroMan 2 GlcN-lPC 18  4′-fluoroMan 2 GlcN-lPC 18  6′-fluoroMan 2 GlcN-lPC 18  2′-aminoMan 2 GlcN-lPC 18  3′-aminoMan 2 GlcN-lPC 18  4′-aminoMan 2 GlcN-lPC 18  6′-aminoMan 2 GlcN-lPC 18   R 2   OH  H  OH  OH  OH  OH  OH  OH  OH  OH  OH  OH  OH  OH  OH  OH   R 3   OH  OH  H  OH  OH  OH  OH  OH  OH  OH  OH  OH  OH  OH  OH  OH   R 4   OH  OH  OH  H  OH  OH  OH  OH  OH  OH  OH  OH  OH  OH  OH 
RESULTS AND DISCUSSION
Synthetic Analogues of Man 2 GlcN-PI. To examine the substrate specificity of the MTIII of trypanosomal GPI biosynthesis, a series of pseudotetrasaccharide analogues of the natural substrate Man 2 GlcN-PI were designed and synthesized ( Figure 2 ). We reasoned that any analogues processed by MTIII might also become substrates for subsequent enzymes in the GPI biosynthetic pathway and so yield additional information. Previous studies examining the substrate specificity of the early enzymes of the T. brucei GPI biosynthetic pathway have shown that the diacylglycerol portion of GlcNAc-PI (1) may be replaced by the simple C 18 alkyl chain of GlcNAc-IPC 18 (3) (23, 24) . Thus, we hypothesized that replacement of the diacylglycerol portion of Man 2 GlcN-PI (4) by a simple C 18 alkyl chain, producing Man 2 GlcN-IPC 18 (5), would not significantly affect recognition of the analogues while simplifying synthesis and making the compounds less susceptible to the action of phospholipases and esterases. A series of 15 analogues of Man 2 GlcN-IPC 18 (6Ϫ20) were synthesized, containing systematic modifications where each of the hydroxyl groups of the two mannose residues were replaced in turn, using hydrogen at each position on the first (6Ϫ8) and non-reducing terminal (second) mannose (9Ϫ12), and fluorine (13Ϫ16) or an amine group (17Ϫ20) at each position on the second mannose residue. The ability of the trypanosomal GPI pathway to recognize and 
The order of the glycolipids in the table reflects their relative migration on hptlc (highest migrating/most hydrophobic first) and for clarity are grouped according to their lipid moiety (Dolichol, PI or IPC 18 ). ND ϭ not determined.
b
Results in species with lower migration, c Results in species with higher migration. process these compounds in vitro is summarized in Figure 1 , panels bϪd and described in detail below.
Synthetic Man 2 GlcN-PI and Man 2 GlcN-IPC 18 Efficiently Prime GPI Biosynthesis. To determine whether synthetic Man 2 GlcN-PI and analogues thereof can prime the trypanosomal GPI pathway in vitro, the cell-free system (i.e., washed trypanosome membranes) was incubated with GDP-[ 3 H]Man in the presence of the compounds to see if they would prime the production of radiolabeled GPI intermediates. The production of endogenous radiolabeled GPI intermediates was prevented by inclusion of N-ethylmaleimide, which inhibits the UDP-GlcNAc:PI ␣1-6 GlcNAc transferase but not the downstream enzymes of GPI biosynthesis (28) , and the production of dolichol cycle intermediates was prevented by the addition of tunicamycin. As a positive control, the production of radiolabeled GPI intermediates was stimulated by the addition of 10 M of synthetic GlcNAc-PI or GlcNAc-IPC 18 (22−24) . The radiolabeled glycolipids were separated by hptlc and visualized by fluorography ( Figure 3, panel a) , and their identities were determined by chemical and enzymatic treatments ( Table 1) . As described previously (22−24), radiolabeled glycolipids produced from GlcNAc-IPC 18 migrate more slowly on hptlc than the corresponding products of GlcNAc-PI as a result of the lower hydrophobicity of their lipid component. The addition of 10 M synthetic Man 2 GlcN-PI produced four radiolabeled downstream products ( Figure 3 , panel a) that were identified as Man 3 GlcN-PI (M 3 ), Man 3 GlcN-(acyl)PI (aM 3 ), EtNPMan 3 -GlcN-(acyl)PI (glycolipid C=), and EtNPMan 3 GlcN-PI (glycolipid A=) (Supplementary Figure S1) . The addition of 10 M synthetic Man 2 GlcNAc-IPC 18 also resulted in the production of the expected products ( Figure 3, panel a) , i.e., those corresponding to M 3 , aM 3 , glycolipid C= and glycolipid A= (Figure 1, panel b) , and two additional products (Supplementary Table S2 and Supplementary Figure S2) . One of these, labeled X, is a GPI of unknown structure (Table 1; Supplementary Table S2 and Supplementary Figure S3 ). However, the other, migrating between M 3 and aM 3 , was shown to be [ Figure S3) . The production of a radiolabeled M 2 species occurred only when priming GPI biosynthesis with Man 2 GlcN-IPC 18 and not when priming with Man 2 GlcN-PI. We considered the possibility that the generation of the [ 3 H]-M 2 species could have arisen from the partial decomposition of Man 2 GlcNAc-IPC 18 to Man 1 GlcNAc-IPC 18 , but none was detected.
Next, we investigated whether Man 2 GlcNAc-IPC 18 might be trimmed back to Man 1 GlcNAc-IPC 18 via ␣-mannosidase activity in the cell-free system. However, the inclusion of the ␣-mannosidase inhibitors swainsonine and kifunensine had no effect (Supplementary Figure  S4) . Thus, we favor a transglycoslyation mechanism (Figure 1, panel c) , and this is discussed later.
Priming GPI Biosynthesis with Man 2 GlcNAc-PI and Man 2 GlcNAc-IPC 18 . GPI biosynthesis in T. brucei proceeds via the de-N-acetylation of GlcNAc-PI to produce GlcN-PI (17), which is strictly required for mannosylation by MTI to form Man 1 GlcN-PI (18) . It has been shown previously that the de-N-acetylase is unable to act on Man 1 GlcNAc-PI, confirming this sequence of events (18) . However, it is not known if the subsequent mannosyltransferases, MTII and MTIII, require the presence of a free amine group to elaborate Man 1 GlcN-PI to Man 2 GlcN-PI and Man 2 GlcN-PI to Man 3 GlcN-PI, respectively. To clarify this situation, we chemically N-acetylated the M 2 analogues, to form Man 2 GlcNAc-PI and Man 2 GlcNAc-IPC 18 , and tested the ability of the cellfree system to process them. Both N-acetylated M 2 analogues were processed to a single prominent product with hydrophobicity slightly higher than the corresponding M 3 analogue (Figure 3, panel b) . The identity of the products as N-acetylated M 3 species was confirmed via chemical N-acetylation, which showed that the products contained no free amine and co-migrated with chemically N-acetylated M 3 standards (Supplementary Figure  S5) . Interestingly, although MTIII can act upon the N-acetylated M 2 analogues, neither the de-N-acetylase nor inositol acyltransferase are able to act upon them or their N-acetylated M 3 products. The additional faint band seen with Man 2 GlcNAc-IPC 18 is probably [ 3 H]-Man 2 GlcNAc-IPC 18 produced by the same putative transglycosylation mechanism described above.
Effects of Systematic Deoxygenation of Man 2 GlcN-IPC 18 . To assess which of the mannose hydroxyl groups of Man 2 GlcN-IPC 18 are important for substrate recognition, we tested the ability of the cell-free system to process a series of analogues where each OH group was replaced by H in turn (compounds 6Ϫ12). Removal of hydroxyl groups from the first mannose (attached directly to GlcN), as in compounds 6Ϫ8, did not prevent recognition and processing by MTIII, such that [ deoxyMan)-GlcN-IPC 18 was processed to the corresponding M 3 product, it did not undergo inositol acylation to form aM 3 , nor did the addition of ethanolamine phosphate occur. This observation reveals that the 4-hydroxyl of the first mannose is important for substrate recognition by the inositol acyltransferase and nicely explains why mannosylation must precede inositol acylation in the T. brucei GPI pathway (19) . The lack of ethanolamine phosphate addition is consistent with previous work showing that prior inositol acylation is necessary for ethanolamine phosphate addition (19) .
Removal of hydroxyl groups from the second mannose residue resulted in the production of radiolabeled glycolipids with migration identical to that of the equivalent fully hydroxylated species from Man 2 GlcN-IPC 18 onward (Figure 4 ). This strongly suggests that the processing of these compounds proceeds via the aforementioned transglycosylation mechanism, whereby the terminal deoxymannose is replaced by [ The inability of MTIII to utilize 2=-substituted analogues is expected, since the 2=-OH is the acceptor site for the third mannose. However, the inability of MTIII to utilize 3=-substituted Man 2 GlcN-IPC 18 analogues suggests that this position is also important for MTIII substrate recognition. The 4=-substituted analogues were processed to M 3 and beyond, without the generation of [ ]-M 2 production with the 3=-and 4=-substituted analogues is in contrast to the situation observed with the 3=-and 4=-deoxy analogues. Interestingly, the processing of the 4=-fluoro analogue does not proceed past the generation of aM 3 , whereas the 4=-amino analogue is processed to glycolipid A=, implying that the 4=-position may be recognized as a hydrogen bond donor site by the ethanolamine phosphate transferase.
Man 2 GlcN-PI Analogues As Inhibitors of GPI Biosynthesis. The 2=-and 3=-substituted Man 2 GlcNAc-IPC 18 analogues (compounds 13, 14, 17 and 18 ) and the 4-deoxy analogue (compound 8) were tested for their ability to act as inhibitors of GPI biosynthesis in vitro. The trypanosome cell-free system was preincubated with 100 M Man 2 GlcNAc-IPC 18 analogues for 5 min prior to the addition of 10 M synthetic GlcNAc-IPC 18 and GDP-[ 3 H]Man to prime GPI production. Only the 4-deoxy and 2=-amino analogues significantly inhibited the production of M 3 and downstream GPI intermediates ( Figure 6, panel a) . The 4-deoxyMan 2 GlcNAc-IPC 18 analogue was processed to the corresponding deoxy-M 3 analogue, as observed previously, but surprisingly, the production of fully hydroxylated M 3 as well as aM 3 was inhibited ( Figure 6, panel a) . However, it is not clear if the 4-deoxyMan 2 GlcNAc-IPC 18 analogue or its deoxy-M 3 product is responsible for the observed inhibition, and the exact molecular target is unclear. Radiometric analysis of the hptlc was unable to resolve deoxy-M 3 and M 2 bands, preventing the accurate determination of the apparent IC 50 , which is estimated as Ͼ10 M (Supplementary Figure S6) .
The 2=-amino analogue prevented the production of M 3 and led to an accumulation of M 2 , demonstrating that inhibition of the MTIII was occurring ( Figure 6 , panel b). Quantitative radiometric analysis of the hptlc showed that MTIII was inhibited with an IC 50 of 1.7 Ϯ 0.2 M (Supplementary Figure S7) . The inhibition of T. brucei GPI biosynthesis by mannosamine in vivo, which also leads to the accumulation of M 2 species, has previously been proposed to occur via the production of ManN-ManGlcN-PI (30) . The synthetic 2=-aminoMan 2 -GlcN-IPC 18 inhibitor, described here, is identical to this species apart from the structure of the lipid moiety. Therefore, our results support the proposed mechanism of inhibition (30, 31) whereby interaction of the acceptor 2=-hydroxyl group with a basic group of the glyco- syltransferase is replaced by a chargeϪcharge interaction with the amino group, which would be protonated under assay conditions. Summary of Substrate Recognition for Enzyme Late in the Trypanosomal GPI Biosynthetic Pathway. The results we have obtained using a series of analogues of Man 2 GlcNAc-PI and a cell-free system to examine the substrate recognition of enzymes late in the trypanosomal GPI pathway are summarized in Figure 7 . The replacement of the natural diacylglycerol lipid moiety with a simple C 18 alkyl chain did not affect the recognition and processing of the analogues by the GPI pathway, in agreement with previous studies using GlcNAc-PI analogues (23, 24) . Substrate recognition by MTIII requires the presence of the hydroxyl groups at the 2-and 3-positions of the reducing terminal mannose, and in contrast to MTI, MTIII does not recognize the amine of the glucosamine residue. This is consistent with earlier work by Brown et al. suggesting that MTIII can act on simple hydrophobic dimannosyl acceptors, implying a lack of recognition of both the glucosamine and inositol moiety (32) . The inositol acyltransferase requires the presence of a hydroxyl group at the 4-position on the first mannose and the presence of a free amine on the glucosamine residue, explaining for the first time the molecular basis behind the requirement for mannosylation prior to inositol acylation in the trypanosomal GPI pathway (19) .
It is known that the structure of the substrate for mammalian MTIII is more complex than that for the corresponding trypanosomal enzyme. The mammalian MTIII substrate both is acylated on the inositol ring and contains EtNP attached to the 2-position of the first mannose residue. Inhibition of EtNP addition to the first mannose by the terpenoid lactone YW3548 leads to accumulation of Man 2 GlcN-(acyl)PI in mammalian cells (33) , strongly suggesting that mammalian MTIII requires the presence of the EtNP to the first mannose for substrate recognition (34) . In contrast, the work presented here shows that substrate recognition by trypanosomal MTIII requires relatively few features of the natural substrate. Combining this information with the knowledge that MTIII may be readily inhibited by the introduction of a positive charge at the position of the acceptor hydroxyl group, we aim to produce more drug-like small molecule inhibitors. Differences in the structures of the substrates for mammalian and trypanosomal MTIII suggest that species-specific inhibition may be an achievable goal. Despite the lack of structural and mechanistic data for MTIII, the chemical biology approach applied here has revealed that the MTIII of GPI biosynthesis is an attractive therapeutic against African sleeping sickness. Hance was purchased from Perkin-Elmer NEN. Aspergillus saitoi ␣(1,2)-mannosidase was purchased from Glyko, serum GPI-specific phospholipase D (GPI-PLD) was used unpurified from human serum, hplc grade solvents were purchased from VWR international Ltd., and all other reagents were purchased from Sigma. (Figure 2 ) will be reported elsewhere (37, 38) . High resolution mass spectrometric data and 1 H NMR spectra for these compounds can be found in Supplementary Table  S3 and Supplementary Figure S8 .
METHODS

Materials. GDP-[2-
The corresponding N-acetyl derivates GlcNAc-PI, GlcNAc-IPC 18 , Man 2 GlcNAc-PI, and Man 2 GlcNAc-IPC 18 were prepared by treatment with acetic anhydride (22) . The identity and purity of the synthetic substrates was assessed by negative ion electrospray-mass spectrometry (ES-MS), and the concentration of stock solutions determined by measurement of the inositol content by selected ion-monitoring GC-MS (39 
